Induction of ovulation of mature oocytes by the maturation-inducing steroid 17,20beta,21-trihydroxy-4-pregnen-3-one in the spotted seatrout.
Incubation of mature, hydrated, follicle-enclosed oocytes of the spotted seatrout, Cynoscion nebulosus, with the maturation-inducing steroid (MIS), 17,20beta,21-trihydroxy-4-pregnen-3-one (20beta-S), for 9-12 h resulted in the appearance of ovulated oocytes in the culture media. The ovulation response was concentration-dependent and steroid-specific. The other teleost MIS, 17, 20beta-dihydroxy-4-pregnen-3-one (17,20beta-P), was also a potent inducer of ovulation, whereas progesterone and 11-deoxycorticosterone did not stimulate ovulation above control levels and partially antagonized the action of 20beta-S. The agonist and antagonist activities of these steroids on ovulation are consistent with their relative binding affinities for the ovarian nuclear progestogen receptor previously characterized in this species. Both the RNA synthesis inhibitor actinomycin D and the protein synthesis inhibitor cycloheximide blocked MIS-induced ovulation. This suggests that induction of ovulation by the MIS is through a genomic mechanism of action, and potentially involves the previously characterized nuclear progestogen receptor. Gonadotropin (hCG)-induced ovulation was blocked by addition of the steroid synthesis inhibitor cyanoketone, which was overcome by the addition of 20beta-S, but not pregnenolone. Thus, the most likely mechanism of gonadotropin-induced ovulation is an increase in the synthesis of the MIS. It is concluded that the processes of final oocyte maturation and ovulation are both regulated by the MIS. Whereas final oocyte maturation is mediated by the 20beta-S membrane receptor (P. Thomas and S. Das, 1997, Biol. Reprod. 57, 999-1007), ovulation is regulated by a genomic mechanism and is potentially mediated by the previously characterized nuclear progestogen receptor.
University of Texas Marine Science Institute, Port Aransas, Texas 78373, USA.
J
J
Pinter
P
P
Thomas
D000818:Animals; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D003350:Cortodoxone / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D009865:Oocytes / Q000187:drug effects*; D010053:Ovary / Q000033:anatomy & histology / Q000187:drug effects; D010060:Ovulation / Q000187:drug effects*; D011372:Progestins / Q000494:pharmacology; D018160:Receptors, Cytoplasmic and Nuclear / Q000187:drug effects; D011980:Receptors, Progesterone / Q000187:drug effects; D014337:Trout / Q000502:physiology*
D006063:Chorionic Gonadotropin; D011372:Progestins; D018160:Receptors, Cytoplasmic and Nuclear; D011980:Receptors, Progesterone; C051954:17,20,21-trihydroxy-4-pregnen-3-one; D003350:Cortodoxone